---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Anti-IL-4 receptor alpha monoclonal antibodies"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Anti-IL-4 receptor alpha monoclonal antibodies. Topics: Dupilumab as add-on treatment after high-dose antihistamines: 2026 international guideline; FDA-approved indication in chronic spontaneous urticaria, ages 2 years and older: dupilumab; Dosage in chronic spontaneous urticaria by age and body weight: dupilumab; CUPID Study A and Study C in anti-IgE-naive participants: Week 24 efficacy in the label; 8 further topics. 12 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/anti-il-4-receptor-alpha-monoclonal-antibodies"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Anti-IL-4 receptor alpha monoclonal antibodies

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Anti-IL-4 Receptor Alpha Monoclonal Antibodies

<a id="topic-2.2.2.1.3-1"></a>

### Dupilumab as add-on treatment after high-dose antihistamines: 2026 international guideline

> “We suggest using dupilumab”
> “as add‐on treatment for patients with CSU unresponsive to high doses of 2nd generation H1‐antihistamines.”
> “Results of Phase 3 studies show the efficacy of dupilumab as add‐on treatment, which is however, likely to be less pronounced than those observed with omalizumab”
> “Currently, urticaria‐specific long‐term safety data are lacking, but existent studies in various diseases reflect a generally favorable safety profile”
> “Available data shows efficacy regardless of low baseline IgE levels for dupilumab, which is different compared to omalizumab where very low IgE values are often a reason for insufficient response”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.3-2"></a>

### FDA-approved indication in chronic spontaneous urticaria, ages 2 years and older: dupilumab

> “Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 2 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. (1.7) Limitations of Use: Not indicated for other forms of urticaria. (1.7)”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.2.2.1.3-3"></a>

### Dosage in chronic spontaneous urticaria by age and body weight: dupilumab

> “2.9 Recommended Dosage for Chronic Spontaneous Urticaria Dosage in Adults The recommended dosage of DUPIXENT for adult patients is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every 2 weeks (Q2W).”
> “For pediatric patients 2 years to 5 years of age with CSU, no initial loading dose is recommended.”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

| Age and body weight | Initial loading dose | Subsequent dosage |
| --- | --- | --- |
| 2 to 5 years, 5 to less than 15 kg | Not applicable | “200 mg (one 200 mg injection) every 4 weeks (Q4W)” |
| 2 to 5 years, 15 to less than 30 kg | Not applicable | “300 mg (one 300 mg injection) every 4 weeks (Q4W)” |
| 6 to 17 years, 15 to less than 30 kg | “600 mg (two 300 mg injections)” | “300 mg every 4 weeks (Q4W)” |
| 6 to 17 years, 30 to less than 60 kg | “400 mg (two 200 mg injections)” | “200 mg every 2 weeks (Q2W)” |
| 6 to 17 years, 60 kg or more | “600 mg (two 300 mg injections)” | “300 mg every 2 weeks (Q2W)” |

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.2.2.1.3-4"></a>

### CUPID Study A and Study C in anti-IgE-naive participants: Week 24 efficacy in the label

> “CUPID Study A and Study C included subjects who remained symptomatic despite H1 antihistamine treatment and were anti-IgE treatment naïve, while CUPID Study B included patients who remained symptomatic despite H1 antihistamine and anti-IgE treatments. The efficacy of DUPIXENT was based only on CUPID Study A and Study C; Study B did not meet the primary endpoint.”
> “The primary endpoint was change from baseline in itch severity score over 7 days (ISS7) at Week 24.”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

| Week 24 outcome | Study A dupilumab (N=68) | Study A placebo (N=68) | Study A difference or odds ratio (95% CI) | Study C dupilumab (N=73) | Study C placebo (N=75) | Study C difference or odds ratio (95% CI) |
| --- | --- | --- | --- | --- | --- | --- |
| ISS7, LS mean change (SE) | “-10.44 (0.92)” | “-6.02 (0.94)” | “-4.42 (-6.84, -2.01)” | “-8.50 (1.39)” | “-6.13 (1.38)” | “-2.37 (-4.48, -0.27)” |
| UAS7, LS mean change (SE) | “-20.99 (1.77)” | “-11.95 (1.81)” | “-9.04 (-13.68, -4.40)” | “-15.61 (2.62)” | “-11.27 (2.61)” | “-4.34 (-8.31, -0.36)” |
| UAS7 ≤6, n (%) | “32 (47.1)” | “16 (23.5)” | “3.23 (1.43, 7.27)” | “29 (39.7)” | “17 (22.7)” | “3.05 (1.32, 7.02)” |
| UAS7 = 0, n (%) | “22 (32.4)” | “9 (13.2)” | “3.09 (1.24, 7.69)” | “22 (30.1)” | “13 (17.3)” | “2.73 (1.15, 6.50)” |

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.2.2.1.3-5"></a>

### CUPID Study A: Week 12 results in the label

> “CUPID Study A showed significant improvement in ISS7 and UAS7 from baseline at Week 12 in the DUPIXENT group (LS mean difference DUPIXENT versus placebo of -2.53 [95% CI: (-4.79, -0.27)] for ISS7 and -5.44 [95% CI: (-9.77, -1.11)] for UAS7). The proportion of patients with UAS7 ≤6 at Week 12 in CUPID Study A was 35.3% in the DUPIXENT group and 17.6% in the placebo group (Odds Ratio: 2.79 [95% CI: (1.22, 6.40)]).”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.2.2.1.3-6"></a>

### CUPID Study B in anti-IgE inadequate responders or intolerant participants: primary endpoint not met

> “CUPID Study B enrolled 108 adult and pediatric patients 12 years of age and older with CSU who were inadequate responders (N=104) to H1 antihistamines and anti-IgE treatments or intolerant (N=4) to anti-IgE therapy.”
> “The DUPIXENT group in CUPID Study B did not meet statistical significance for reduction in the primary endpoint ISS7 at Week 24.”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.2.2.1.3-7"></a>

### LIBERTY-CSU CUPID Study A and Study B: phase 3 publication

> “In LIBERTY-CSU CUPID Study A, patients were omalizumab-naive (n = 138, aged ≥6 years). In Study B, patients were omalizumab-intolerant/incomplete responders (n = 108, aged ≥12 years).”
> “In Study A, UAS7 and ISS7 improved with dupilumab versus placebo (difference -8.5 [95% CI, -13.2 to -3.9; P = .0003] and -4.2 [95% CI, -6.6 to -1.8; P = .0005]). In Study B, tested at α = 0.043 after interim analysis, UAS7 improved (difference -5.8 [95% CI, -11.4 to -0.3; P = .0390]), with a numerical trend in ISS7 (difference -2.9 [95% CI, -5.7 to -0.07; nominal P = .0449, not significant]).”
> “Although the primary end point for Study B was not met, dupilumab effects were small in patients who were omalizumab-intolerant/incomplete responders.”

Source: [Maurer et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38431226/)

<a id="topic-2.2.2.1.3-8"></a>

### Adverse reactions in pooled CUPID Studies A, B, and C and immunogenicity in CSU: dupilumab

> “A total of 392 adult and pediatric subjects 12 years of age and older with CSU were evaluated for safety in three randomized, double-blind, parallel-group, multicenter, placebo-controlled, studies, Study A, B, and C, conducted under a master protocol (CUPID) for 36 weeks”
> “No new adverse reactions were identified in pediatric subjects aged 2 to 11 years who received DUPIXENT.”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

| Pooled CUPID Study A, B, and C | Dupilumab 200 mg or 300 mg Q2W (N=195) | Placebo (N=197) |
| --- | --- | --- |
| Injection site reactions, n (%) | “20 (10.3)” | “16 (8.1)” |

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

| CSU population and regimen | Positive anti-drug antibody | Persistent anti-drug antibody | Neutralizing antibody |
| --- | --- | --- | --- |
| Adults and 12 years or older, 200 mg Q2W or 300 mg Q2W through 24 weeks | “9/193 (5%)” | “1/193 (1%)” | “2/9 (22%)” |

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.2.2.1.3-9"></a>

### Efficacy by baseline serum IgE level: dupilumab

> “Improvements in ISS7 and UAS7 at Week 24 were consistent regardless of the patients’ baseline IgE level.”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

> “Dupilumab treatment improved ISS7, UAS7, and HSS7 over 12 and 24 weeks, regardless of baseline serum IgE level (interaction p ≥ 0.59 for all treatment by subgroup comparisons), with weak correlations ( r < 0.2) observed between IgE level changes and ISS7, UAS7, and HSS7 outcomes.”
> “In the current analysis, baseline total IgE had no predictive value as a dupilumab treatment response biomarker in CSU.”

Source: [Maurer et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11393262/)

<a id="topic-2.2.2.1.3-10"></a>

### Dupilumab in a network meta-analysis of systemic treatments for the Joint Task Force guideline update

> “We systematically synthesized the comparative benefits and harms of systemic treatments for chronic urticaria.”
> “As part of updating the AAAAI/ACAAI JTFPP chronic urticaria guidelines”
> “Random effects Bayesian network meta-analyses addressed urticaria activity (comprising itch and wheal scores), angioedema activity, health-related quality of life, and adverse events.”
> “Dupilumab improved urticaria activity, but its impact on quality of life is uncertain, and no dupilumab trials addressed angioedema activity.”
> “Dupilumab (MD −6.01 [95% CrI −10.57 to −1.46]; moderate certainty) is likely among the most effective”
> “Cyclosporine (MD −8.25 [95% CrI −18.11 to 1.61]; low certainty) and dupilumab (MD −9.73 [95% CrI −21.51 to 2.05]; low certainty) may be better than placebo.”

Source: [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004)

<a id="topic-2.2.2.1.3-11"></a>

### Dupilumab compared with omalizumab and remibrutinib: network meta-analysis of 15 studies

> “This study aims to compare the relative efficacy of omalizumab, dupilumab, and remibrutinib in CSU.”
> “Frequentist random-effects network meta-analysis were conducted in R.”
> “Fifteen studies (4,913 patients) were included.”
> “Dupilumab provided sustained itch relief but delayed efficacy.”

Source: [Xiong et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41186128/)

<a id="topic-2.2.2.1.3-12"></a>

### Matching-adjusted indirect comparison of omalizumab with dupilumab: analysis with Genentech involvement

> “To overcome this limitation, we used matching-adjusted indirect comparison to assess the efficacy of omalizumab versus dupilumab in primary phase 3 trials.”
> “Pooled patient-level data from the omalizumab ASTERIA I/II trials ( NCT01287117 /01292473) were compared with published aggregate data from the dupilumab LIBERTY-CSU CUPID Study A trial ( NCT04180488 ).”
> “Improvements in both disease activity and itch severity were statistically significantly greater for omalizumab versus dupilumab (least squares mean [95% confidence interval] difference: UAS7, −7.6 [−13.0, −2.2], P = .006; ISS7, −3.0 [−5.8, −0.3], P = .031).”
> “Genentech Inc was involved in the study design, data analysis, and preparation of the report.”

Source: [Mosnaim et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12990347/)

Additional sources: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
